Cargando…
The Interaction Between Pulmonary Fibrosis and COVID-19 and the Application of Related Anti-Fibrotic Drugs
COVID-19 is a highly contagious respiratory disease, which mainly affects the lungs. Critically ill patients are easily complicated by cytokine storms, acute respiratory distress syndrome (ARDS), and respiratory failure, which seriously threaten their lives. Pulmonary fibrosis (PF) is a common inter...
Autores principales: | Shen, Hao, Zhang, Nu, Liu, Yuqing, Yang, Xuerong, He, Yuanyuan, Li, Qi, Shen, Xiaoyan, Zhu, Yulian, Yang, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766975/ https://www.ncbi.nlm.nih.gov/pubmed/35069217 http://dx.doi.org/10.3389/fphar.2021.805535 |
Ejemplares similares
-
Anti-Fibrotic Effects of Low Toxic Microcystin-RR on Bleomycin-Induced Pulmonary Fibrosis: A Comparison with Microcystin-LR
por: Wang, Jie, et al.
Publicado: (2021) -
Novel Anti-fibrotic Therapies
por: McVicker, Benita L., et al.
Publicado: (2017) -
Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis
por: Yang, Xuerong, et al.
Publicado: (2022) -
The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics
por: Guo, Xirui, et al.
Publicado: (2021) -
An Adaptogen: Withaferin A Ameliorates in Vitro and in Vivo Pulmonary Fibrosis by Modulating the Interplay of Fibrotic, Matricelluar Proteins, and Cytokines
por: Bale, Swarna, et al.
Publicado: (2018)